Breast最新文献

{"title":"“Perspective: An integrated vision of the quality of life in breast cancer survivorship trajectory”","authors":"Chiara Marzorati , Marianna Masiero , Gabriella Pravettoni","doi":"10.1016/j.breast.2024.103785","DOIUrl":"10.1016/j.breast.2024.103785","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103785"},"PeriodicalIF":5.7,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001164/pdfft?md5=f4c4158137f344f64e5bbdb95dc803cf&pid=1-s2.0-S0960977624001164-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142088013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis of intraoperative electron radiation therapy for partial breast irradiation in early breast cancer","authors":"Patrick Maisonneuve, Roberto Orecchia","doi":"10.1016/j.breast.2024.103787","DOIUrl":"10.1016/j.breast.2024.103787","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103787"},"PeriodicalIF":5.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001188/pdfft?md5=7ce3e066efc8900827a2d45614208d3c&pid=1-s2.0-S0960977624001188-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141998073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the risk of major adverse cardiac events following radiotherapy for left breast cancer using a modified generalized Lyman normal-tissue complication probability model","authors":"Tzu-Yu Lai ,&nbsp;Yu-Wen Hu ,&nbsp;Ti-Hao Wang ,&nbsp;Jui-Pin Chen ,&nbsp;Cheng-Ying Shiau ,&nbsp;Pin-I Huang ,&nbsp;I-Chun Lai ,&nbsp;Yu-Ming Liu ,&nbsp;Chi-Cheng Huang ,&nbsp;Ling-Ming Tseng ,&nbsp;Nicole Huang ,&nbsp;Chia-Jen Liu","doi":"10.1016/j.breast.2024.103788","DOIUrl":"10.1016/j.breast.2024.103788","url":null,"abstract":"<div><h3>Background</h3><p>We introduced an adapted Lyman normal-tissue complication probability (NTCP) model, incorporating clinical risk factors and censored time-to-event data, to estimate the risk of major adverse cardiac events (MACE) following left breast cancer radiotherapy (RT).</p></div><div><h3>Materials and methods</h3><p>Clinical characteristics and MACE data of 1100 women with left-side breast cancer receiving postoperative RT from 2005 to 2017 were retrospectively collected. A modified generalized Lyman NTCP model based on the individual left ventricle (LV) equivalent uniform dose (EUD), accounting for clinical risk factors and censored data, was developed using maximum likelihood estimation. Subgroup analysis was performed for low-comorbidity and high-comorbidity groups.</p></div><div><h3>Results</h3><p>Over a median follow-up 7.8 years, 64 patients experienced MACE, with higher mean LV dose in affected individuals (4.1 Gy vs. 2.9 Gy). The full model accounting for clinical factors identified <em>D</em>_<em>50</em> = 43.3 Gy, <em>m</em> = 0.59, and <em>n</em> = 0.78 as the best-fit parameters. The threshold dose causing a 50 % probability of MACE was lower in the high-comorbidity group (<em>D</em>_<em>50</em> = 30 Gy) compared to the low-comorbidity group (<em>D</em>_<em>50</em> = 45 Gy). Predictions indicated that restricting LV EUD below 5 Gy yielded a 10-year relative MACE risk less than 1.3 and 1.5 for high-comorbidity and low-comorbidity groups, respectively.</p></div><div><h3>Conclusion</h3><p>Patients with comorbidities are more susceptible to cardiac events following breast RT. The proposed modified generalized Lyman model considers nondosimetric risk factors and addresses incomplete follow-up for late complications, offering comprehensive and individualized MACE risk estimates post-RT.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103788"},"PeriodicalIF":5.7,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S096097762400119X/pdfft?md5=e1cfaf65c5238f23c38f51e2f3bbe5a6&pid=1-s2.0-S096097762400119X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive prediction of axillary lymph node dissection exemption in breast cancer patients post-neoadjuvant therapy: A radiomics and deep learning analysis on longitudinal DCE-MRI data","authors":"Yushuai Yu ,&nbsp;Ruiliang Chen ,&nbsp;Jialu Yi ,&nbsp;Kaiyan Huang ,&nbsp;Xin Yu ,&nbsp;Jie Zhang ,&nbsp;Chuangui Song","doi":"10.1016/j.breast.2024.103786","DOIUrl":"10.1016/j.breast.2024.103786","url":null,"abstract":"<div><h3>Purpose</h3><p>In breast cancer (BC) patients with clinical axillary lymph node metastasis (cN+) undergoing neoadjuvant therapy (NAT), precise axillary lymph node (ALN) assessment dictates therapeutic strategy. There is a critical demand for a precise method to assess the axillary lymph node (ALN) status in these patients.</p></div><div><h3>Materials and methods</h3><p>A retrospective analysis was conducted on 160 BC patients undergoing NAT at Fujian Medical University Union Hospital. We analyzed baseline and two-cycle reassessment dynamic contrast-enhanced MRI (DCE-MRI) images, extracting 3668 radiomic and 4096 deep learning features, and computing 1834 delta-radiomic and 2048 delta-deep learning features. Light Gradient Boosting Machine (LightGBM), Support Vector Machine (SVM), RandomForest, and Multilayer Perceptron (MLP) algorithms were employed to develop risk models and were evaluated using 10-fold cross-validation.</p></div><div><h3>Results</h3><p>Of the patients, 61 (38.13 %) achieved ypN0 status post-NAT. Univariate and multivariable logistic regression analyses revealed molecular subtypes and Ki67 as pivotal predictors of achieving ypN0 post-NAT. The SVM-based “Data Amalgamation” model that integrates radiomic, deep learning features, and clinical data, exhibited an outstanding AUC of 0.986 (95 % CI: 0.954–1.000), surpassing other models.</p></div><div><h3>Conclusion</h3><p>Our study illuminates the challenges and opportunities inherent in breast cancer management post-NAT. By introducing a sophisticated, SVM-based “Data Amalgamation” model, we propose a way towards accurate, dynamic ALN assessments, offering potential for personalized therapeutic strategies in BC.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103786"},"PeriodicalIF":5.7,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001176/pdfft?md5=6038c7edb2a3b27da76fa99d12532300&pid=1-s2.0-S0960977624001176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of oncoplastic breast-conserving surgery versus conventional breast-conserving surgery: An updated meta-analysis","authors":"Rui Tian ,&nbsp;Yu Zheng ,&nbsp;Ruikang Liu ,&nbsp;Chen Jiang ,&nbsp;Hongmei Zheng","doi":"10.1016/j.breast.2024.103784","DOIUrl":"10.1016/j.breast.2024.103784","url":null,"abstract":"<div><h3>Introduction</h3><p>Breast cancer is the most common cancer among women. The surgical treatment of breast cancer has transitioned progressively from radical mastectomy to breast-conserving surgery. In this meta-analysis, we are aiming to compare oncoplastic breast-conserving surgery (OS) with conventional breast-conserving surgery (BCS) in terms of efficacy and safety.</p></div><div><h3>Methods</h3><p>We searched Medline, Web of Science, Embase, Cochrane databases, <span><span>Clinicaltrial.gov</span><svg><path></path></svg></span>, and CNKI until April 30, 2024. Data from cohort studies and randomized controlled trials (RCTs) were included. Outcomes included primary outcomes (re-excision, local recurrence, positive surgical margin, mastectomy), secondary outcomes and safety outcomes. The Cochrane Risk of Bias Assessment Tool and Newcastle-Ottawa Scale were used to evaluate the quality of outcomes.</p></div><div><h3>Results</h3><p>Our study included 52 studies containing 46,835 patients. Primary outcomes comprise re-excision, local recurrence, positive surgical margin, and mastectomy, there were significant differences favoring OS over BCS (RR 0.68 [0.56, 0.82], RR 0.62 [0.47, 0.82], RR 0.76 [0.59, 0.98], RR 0.66 [0.44, 0.98] respectively), indicating superior efficacy of OS. Additionally, OS demonstrated significant aesthetic benefits (RR 1.17 [1.03, 1.33] and RR 1.34 [1.18, 1.52]). While total complications were significantly fewer in the OS group (RR 0.70 [0.53, 0.94]), the differences in specific complications were not significant. Furthermore, subgroup analyses were conducted based on nationality, sample size, quality, and type.</p></div><div><h3>Conclusion</h3><p>OS demonstrates either superior or at least comparable outcomes across various aspects when compared to BCS.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103784"},"PeriodicalIF":5.7,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001152/pdfft?md5=6eae8c5fe3b026bff1fe400b19aa2d71&pid=1-s2.0-S0960977624001152-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141911623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up","authors":"A. Dezellus ,&nbsp;S. Mirallie ,&nbsp;F. Leperlier ,&nbsp;B. Sauterey ,&nbsp;P.-E. Bouet ,&nbsp;A. Dessaint ,&nbsp;S. Duros ,&nbsp;A.S. Gremeau ,&nbsp;M.-A. Mouret-Reynier ,&nbsp;L.M. Durand ,&nbsp;L. Venat ,&nbsp;P. De Blay ,&nbsp;M. Robert ,&nbsp;T. Freour ,&nbsp;M. Campone ,&nbsp;A. Blanc-Lapierre ,&nbsp;V. Bordes","doi":"10.1016/j.breast.2024.103776","DOIUrl":"10.1016/j.breast.2024.103776","url":null,"abstract":"<div><h3>Purpose</h3><p>Fertility issues are of great concern for young women undergoing treatment for breast cancer (BC). Fertility preservation (FP) protocols using controlled ovarian stimulation (COS) with letrozole have been widely used with overall good results. However, letrozole cannot be used in every country in this context. This study aimed to assess the efficacy of tamoxifen for COS in women with early BC undergoing FP.</p></div><div><h3>Methods</h3><p>This multicentric prospective study included patients aged 18–40, diagnosed with stage I, II and III invasive BC, undergoing tamoxifen-COS before adjuvant or neoadjuvant chemotherapy (NAC). The primary endpoint was the efficacy of tamoxifen-COS protocol evaluated by the number of oocytes collected and vitrified. Secondary endpoints included the time interval before chemotherapy, breast cancer (BC) recurrence rates, and reproductive outcomes.</p></div><div><h3>Results</h3><p>Ninety-five patients were included between 2014 and 2017, aged 31.5 ± 4 years on average. 37.9 % received NAC and 62.1 % received adjuvant chemotherapy. FP procedure was successful in 89.5 % of the cycles. The mean number of collected and vitrified oocytes was 12.8 ± 7.9 and 9.8 ± 6.2, respectively. The mean duration of COS was 10.4 ± 1.9 days. Median time before chemotherapy initiation was 3.6 weeks (IQR 3.1; 4.1) for women receiving NAC. Five-year relapse-free and overall survival rates were in-line with those expected in this population. Twenty-one women had spontaneous full-term pregnancies, while 5 underwent IVF cycles with frozen-thawed oocytes, without pregnancy.</p></div><div><h3>Conclusion</h3><p>Tamoxifen-COS protocols appear to be feasible before adjuvant or NAC treatment in young BC patients and efficient in terms of oocyte yield.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103776"},"PeriodicalIF":5.7,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001073/pdfft?md5=8106c9676dbb3345d870b5d8a2d83bcb&pid=1-s2.0-S0960977624001073-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study","authors":"José Enrique Alés-Martínez ,&nbsp;Judith Balmaña ,&nbsp;Pedro Sánchez-Rovira ,&nbsp;Francisco Javier Salvador Bofill ,&nbsp;Jose Ángel García Sáenz ,&nbsp;Isabel Pimentel ,&nbsp;Serafín Morales ,&nbsp;María Fernández-Abad ,&nbsp;Ainhara Lahuerta Martínez ,&nbsp;Neus Ferrer ,&nbsp;Pilar Zamora ,&nbsp;Begoña Bermejo ,&nbsp;Tamara Díaz-Redondo ,&nbsp;María Helena López-Ceballos ,&nbsp;María Galán ,&nbsp;Jhudit Pérez-Escuredo ,&nbsp;Laura Calabuig ,&nbsp;Miguel Sampayo ,&nbsp;José Manuel Pérez-Garcia ,&nbsp;Javier Cortés ,&nbsp;Antonio Llombart-Cussac","doi":"10.1016/j.breast.2024.103780","DOIUrl":"10.1016/j.breast.2024.103780","url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate the efficacy and safety of the combination of olaparib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC) and germinal <em>BRCA</em> mutations (<em>gBRCAm)</em>.</p></div><div><h3>Methods</h3><p>OPHELIA (NCT03931551) was a single-arm, open-label, phase 2 clinical trial. Patients aged ≥18 years diagnosed with HER2-positive ABC with germinal deleterious mutations in <em>BRCA1</em> or <em>BRCA2</em> who had received at least one prior systemic regimen for advanced disease were enrolled. Patients received olaparib plus trastuzumab until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was investigator-assessed clinical benefit rate for at least 24 weeks as per RECIST v.1.1. Key secondary endpoints included overall response rate (ORR) and safety profile.</p></div><div><h3>Results</h3><p>A total of 68 pre-treated HER2-positive ABC patients were screened. Due to slow accrual the trial was stopped after enrolling 5 patients instead of the planned sample size of 20. Four patients achieved clinical benefit (80.0 %, 95 % CI; 28.4–99.5, p &lt; 0.001) and the primary endpoint was met. The ORR was 60.0 % (95 % CI; 14.7–94.7), including one complete response. Four (80.0 %) patients experienced at least one treatment-related treatment-emergent adverse event (TEAE). Most TEAEs were grade 1 or 2. There were no treatment-related deaths and no new safety signals were identified.</p></div><div><h3>Conclusions</h3><p>This study suggests that the combination of olaparib plus trastuzumab may be effective and safe in pre-treated patients with HER2-positive g<em>BRCA</em>m ABC. This ABC patient population should be further studied and not be pre-emptively excluded from clinical trials of targeted therapy for <em>BRCA1/2</em>-driven cancers.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103780"},"PeriodicalIF":5.7,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001115/pdfft?md5=20d3f93336a801c524354de317ea6580&pid=1-s2.0-S0960977624001115-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141905911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Women's views on using artificial intelligence in breast cancer screening: A review and qualitative study to guide breast screening services","authors":"Stacy M. Carter ,&nbsp;Diana Popic ,&nbsp;M. Luke Marinovich ,&nbsp;Lucy Carolan ,&nbsp;Nehmat Houssami","doi":"10.1016/j.breast.2024.103783","DOIUrl":"10.1016/j.breast.2024.103783","url":null,"abstract":"<div><p>As breast screening services move towards use of healthcare AI (HCAI) for screen reading, research on public views of HCAI can inform more person-centered implementation. We synthesise reviews of public views of HCAI in general, and review primary studies of women's views of AI in breast screening. People generally appear open to HCAI and its potential benefits, despite a wide range of concerns; similarly, women are open towards AI in breast screening because of the potential benefits, but are concerned about a wide range of risks. Women want radiologists to remain central; oversight, evaluation and performance, care, equity and bias, transparency, and accountability are key issues; women may be less tolerant of AI error than of human error. Using our recent Australian primary study, we illustrate both the value of informing participants before collecting data, and women's views. The 40 screening-age women in this study stipulated four main conditions on breast screening AI implementation: 1) maintaining human control; 2) strong evidence of performance; 3) supporting familiarisation with AI; and 4) providing adequate reasons for introducing AI. Three solutions were offered to support familiarisation: transparency and information; slow and staged implementation; and allowing women to opt-out of AI reading. We provide recommendations to guide both implementation of AI in healthcare and research on public views of HCAI. Breast screening services should be transparent about AI use and share information about breast screening AI with women. Implementation should be slow and staged, providing opt-out options if possible. Screening services should demonstrate strong governance to maintain clinician control, demonstrate excellent AI system performance, assure data protection and bias mitigation, and give good reasons to justify implementation. When these measures are put in place, women are more likely to see HCAI use in breast screening as legitimate and acceptable.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103783"},"PeriodicalIF":5.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001140/pdfft?md5=83d2c658a374419e8fb05923de2eb3d0&pid=1-s2.0-S0960977624001140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141900994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative complications of hypofractionated and conventional fractionated radiation therapy in patients with implant-based breast reconstruction: A systematic review and meta-analysis","authors":"Seong-Hyuk Park ,&nbsp;Yun-Jung Yang ,&nbsp;Sihyun Sung ,&nbsp;Yelim Choi ,&nbsp;Eun-Jung Yang","doi":"10.1016/j.breast.2024.103782","DOIUrl":"10.1016/j.breast.2024.103782","url":null,"abstract":"<div><h3>Introduction</h3><p>Post-mastectomy radiation therapy is an important component of adjuvant therapy for high-risk patients. However, radiation to reconstructed breasts can cause various complications. Recently, hypofractionated (HF) protocols have been adopted in several countries. Here, we aimed to assess the impact of HF protocols on implant-reconstructed breasts through a meta-analysis and systematic review of the currently available literature.</p></div><div><h3>Methods</h3><p>Records published until August 2023 were systematically searched in PubMed, Cochrane Library, and EMBASE databases. Keywords included hypofractionation radiotherapy, mastectomy, and breast reconstruction. Studies that utilized HF and conventional fractionation (CF) after prosthetic reconstruction were selected. Due to the rarity of events in outcomes, Mantel-Haenszel's odds ratios were calculated using a fixed-effect model to compare the complication rates between HF and CF groups. For analysis with high heterogeneity, a random effect model was used.</p></div><div><h3>Results</h3><p>Seven articles with 924 implant reconstructions, in which 506 (54.8 %) underwent HF were included. HF patients received 43.8 Gy on average, while CF patients received 51.2 Gy. Mean follow-up ranged from 10.6 to 35 months. Seven studies were included in the meta-analysis. HF groups had a significantly lower risk of capsular contracture (OR 0.25, 95 % CI 0.11–0.55), major revision surgery (OR 0.19, 95 % CI 0.05–0.80), and wound dehiscence (OR 0.24, 95 % CI 0.07–0.78) compared to CF groups. The risks of other complications were not statistically significant.</p></div><div><h3>Conclusion</h3><p>This study indicates that HF protocols are associated with fewer complications than CF protocols in implant-reconstructed patients. These findings suggest that the application of HF PMRT in implant-reconstructed patients with breast cancer is plausible.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103782"},"PeriodicalIF":5.7,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001139/pdfft?md5=5c5217518673886debbc77b1bf2c3e24&pid=1-s2.0-S0960977624001139-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141852256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study","authors":"Caterina Caminiti ,&nbsp;Giuseppe Maglietta ,&nbsp;Laura Arenare ,&nbsp;Raimondo Di Liello ,&nbsp;Gessica Migliaccio ,&nbsp;Daniela Barberio ,&nbsp;Michelino De Laurentiis ,&nbsp;Francesca Di Rella ,&nbsp;Francesco Nuzzo ,&nbsp;Carmen Pacilio ,&nbsp;Giovanni Iodice ,&nbsp;Michele Orditura ,&nbsp;Fortunato Ciardiello ,&nbsp;Sara Di Bella ,&nbsp;Luigi Cavanna ,&nbsp;Camillo Porta ,&nbsp;Filippo Giovanardi ,&nbsp;Carla Ida Ripamonti ,&nbsp;Domenico Bilancia ,&nbsp;Giuseppe Aprile ,&nbsp;Francesco Perrone","doi":"10.1016/j.breast.2024.103781","DOIUrl":"10.1016/j.breast.2024.103781","url":null,"abstract":"<div><p>Patients’ self-reporting is increasingly considered essential to measure quality-of-life and treatment-related side-effects. However, if multiple patient-reported instruments are used, redundancy may represent an overload for patients.</p><p>Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) are a tool allowing direct patients’ reporting of side-effects.</p><p>We tested psychometric properties of a selected list of PRO-CTCAE items, in a cohort of 303 breast cancer patients, using validated instruments for quality of life assessment as anchors.</p><p>The analysis of convergent validity with HADS (Hospital Anxiety and Depression Scale) and EORTC BR-23 sub-scales, and the analysis of responsiveness with the PGIC (Patients Global Impression of Change) score supported that a selected list of PRO-CTCAE symptoms might represent a standardized, agile tool for both research and practice settings to reduce patient burden without missing relevant information on patient perceptions.</p><p>Among patients using digital devices, those with a higher education levels required shorter time to fulfil questionnaires.</p><p>In conclusion, a selected list of PRO-CTCAE items can be considered as a standardized, agile tool for capturing crucial domains of side-effects and quality of life in patients with breast cancer.</p><p>The study is registered on <span><span>clinicaltrials.gov</span><svg><path></path></svg></span> (NCT04416672).</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103781"},"PeriodicalIF":5.7,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001127/pdfft?md5=52c5e20e7eec89e76b7bbf7bc9e19727&pid=1-s2.0-S0960977624001127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}